Polydex Pharmaceuticals likes its molecules nice and large. Polydex company produces biotech and specialty chemical ingredients for use in veterinary medicines. One of Polydex's leading products, iron dextran, is used to treat anemia in piglets. Polydex sells dextran and derivatives worldwide through subsidiaries Dextran Products and Chemdex. Taking a shot at human pharmaceuticals, the company developed a microbicidal gel for potential use as a contraceptive and prevention of sexually transmitted diseases. However, development of the product was suspended pending further investigation. Chairman, president, and CEO George Usher and his family control 47% of the voting stock of the company.

Pharming Group N.V. is a Netherlands-based biotechnology company. The Company has facilities both in the Netherlands and the United States. Pharming develops products for the treatment of diseases with significant medical needs, including genetic disorders, diseases associated with the immune system, ageing diseases, and nutritional products. The Company’s technologies include platforms for the production of protein therapeutics and technology and processes for the purification and formulation of these products, as well as technologies in the field of DNA repair via its subsidiary DNage BV. Pharming products under development are divided into three categories: biopharmaceuticals, biomaterials, and bio-nutritionals. Products in the most advanced stage of development and closest to commercialization are Rhucin and human lactoferrin for use in food products. Pharming has several partnerships and collaborations with, inter alia, AgResearch, US Army, Aslan and Schering-Plough.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

Eli Lilly and Company was founded in 1876 and is based in Indianapolis, Indiana. Eli Lilly and Company develops, manufactures, and sells pharmaceutical products worldwide. It offers neuroscience products to treat schizophrenia, manic episodes, and bipolar maintenance; depression and diabetic peripheral neuropathic pain; attention-deficit hyperactivity disorder in children, adolescents, and adults; depression, bulimia nervosa, and obsessive-compulsive disorders; and bipolar depression. The company's endocrinology products are used for diabetes; type 2 diabetes; osteoporosis in postmenopausal women; osteoporosis in postmenopausal women and men at high risk for fracture; and human growth hormone deficiency and idiopathic short stature.Eli Lilly and Company also provides oncology products to prevent pancreatic, metastatic breast, non-small cell lung, ovarian, and bladder cancers; malignant pleural mesothelioma; and colorectal cancers, as well as offers cardiovascular products for treating erectile dysfunction, atherothrombotic events in patients with acute coronary syndromes undergoing percutaneous coronary invention and adults with severe sepsis at high risk of death. In addition, the company offers animal health products, such as cattle feed additives; antibiotics used to treat respiratory diseases and other diseases in cattle, swine, and poultry; protein supplements to improve milk productivity in dairy cows; anticoccidial agents for use in poultry; antibiotics used to control enteric infections in calves and swine; parasiticides for use on cattle and premises; and products that prevents flea infestations on dogs, as well as other pharmaceutical products to treat staphylococcal infections and bacterial infections. Eli Lilly distributes its products principally through independent wholesale distributors, as well as directly to pharmacies. It has a strategic alliance with MacroGenics, Inc.; and licensing and development agreements with TransPharma Medical Ltd. and BioMS Medical Corp.

Laboratorio Chile S.A. makes branded, generic, and OTC drugs, including treatments for respiratory and infectious diseases, as well as cardiovascular, neurological, pain management, and hormone therapy products. Laboratorio Chile also makes such consumer fare as sweetener Marco Sweet, nutritional supplement Esvit-C, and Freshmel antiseptic throat lozenges. The company markets its wares in over a dozen Latin American countries.

IntelliPharmaCeutics International (IPC) is getting smarter about drug delivery by the second. The pharmaceutical company uses its controlled release drug delivery technology to develop new and generic drug products for enhanced treatment of pain, cardiovascular, and neurological issues. Its products are based on its patented HYPERMATRIX platform, which controls a drug's release time within the gastrointestinal tract. With a diverse pipeline, IPC develops its own proprietary products, as well as ones for third parties, including international clients; it also offers contract manufacturing. In 2009 the formerly private company merged with Vasogen to create the publicly traded IntelliPharmaCeutics International.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Integrated DNA Technologies (IDT) is there when you need some genetic materials in a pinch. The company supplies oligonucleotides (oligos), which are essentially short strands of DNA, to research and development entities. Oligos are used to develop new drugs, create diagnostic tests for genetic and infectious diseases, and develop agricultural products. IDT custom-makes the strands using chemical DNA synthesis machines that can create the oligos within a day after the company has received an order. Founded in 1987, IDT has offices in Australia, Belgium, Canada, Russia, and the US; it also has distributors in some 20 other countries in Africa, Asia, Europe, the Americas, and the Middle East.

SuperGen was founded in 1991 and is based in Dublin, California. SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on developing MP-470, a DNA repair suppressor; SGI-1776, a PIM kinase inhibitor; MP-529, an Aurora kinase inhibitor; SGI-110, a DNMT1 inhibitor; and SGI-1252, a JAK2 inhibitor. SuperGen also has an approved product, Mitozytrex for the treatment of solid tumors. In addition, the company is developing Orathecin, a Phase III clinical trial product for the treatment of solid tumors; Partaject busulfan, a Phase I/II clinical trial product for neoplastic meningitis/bone marrow transplant; Partaject Orathecin, a non-clinical stage product for the treatment of solid tumors; and CZ 112, a Phase I clinical trial product for the treatment of solid tumors. It is also developing Cremophor-free paclitaxel, a non-clinical stage product for the treatment of solid tumors; Avicine, a therapeutic vaccine for the treatment of cancer, which is in Phase II trial; VEGF, a non-clinical stage product for the treatment of anti-angiogenesis; PZG, a Phase II clinical trial product for the treatment of type II diabetes; and AM454, a phosphocholine derivative, which is in non-clinical stage for obesity/diabetes. The company sells its products to clinics, hospitals, hospital buying groups, drug distributors, and wholesalers in the United States and Europe. It has a collaboration agreement with GlaxoSmithKline Inc. to discover and develop cancer therapeutics based on epigenetic targets.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.